Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis

作者全名："Hu, Di; Zhou, Yan-Yan; Ma, Hong-Bo; Tao, Miao-Miao; Huang, Qun-Zhen; Yang, Zhen-Zhou; Zhou, Qi"

作者地址："[Hu, Di; Yang, Zhen-Zhou; Zhou, Qi] Chongqing Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China; [Hu, Di; Ma, Hong-Bo; Tao, Miao-Miao; Huang, Qun-Zhen; Zhou, Qi] Chongqing Univ, Fuling Hosp, Chongqing, Peoples R China; [Zhou, Yan-Yan] Dalian Med Univ, Liaoning, Peoples R China"

通信作者："Yang, ZZ; Zhou, Q (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China.; Zhou, Q (通讯作者)，Chongqing Univ, Fuling Hosp, Chongqing, Peoples R China."

来源：BMC PULMONARY MEDICINE

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001010574200002

JCR分区：Q2

影响因子：2.6

年份：2023

卷号：23

期号：1

开始页：　

结束页：　

文献类型：Review

关键词：NSCLC; EGFR mutation; EGFR-TKIs; Angiogenesis inhibitors; Meta-analysis

摘要："Background For patients with advanced non-small-cell lung cancer (NSCLC) with EGFR mutations, the suggested course of action is epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Even with a high disease control rate, a majority of patients develop acquired EGFR-TKIs resistance and eventually advance. To increase the benefits of treatment, clinical trials are increasingly exploring the value of EGFR-TKIs combined with angiogenesis inhibitors as a first-line treatment in advanced NSCLC carrying EGFR mutations. Method Using PubMed, EMBASE and Cochrane Library, to locate published full-text articles in print or online, a thorough literature search was done from the database's inception to February 2021. Additionally, oral presentation RCTs from ESMO and ASCO were obtained. We sifted out RCTs that used EGFR-TKIs along with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant NSCLC. ORR, AEs, OS, and PFS were the endpoints. Review Manager version 5.4.1 was used for data analysis. Results One thousand eight hundred twenty-one patients were involved in 9 RCTs. According to the results, combining EGFR-TKIs with angiogenesis inhibitors therapy prolonged PFS of advanced EGFR-mutation NSCLC patients on the whole [HR:0.65 (95%CI: 0.59 similar to 0.73, P<0.00001)]. No significant statistical difference was identified between the combination group and single drug group in OS(P=0.20) and ORR (P=0.11). There are more adverse effects when EGFR-TKIs are used in combination with angiogenesis inhibitors than when used alone. Conclusion The combination of EGFR-TKIs and angiogenesis inhibitors prolonged PFS in patients with EGFR-mutant advanced NSCLC, but the OS and ORR benefit was not significant, and the risk of adverse events was higher, more pronounced with hypertension and proteinuria; PFS in subgroups suggested that the combination was associated with better PFS in the smoking, liver metastasis, and no brain metastasis groups, and the included studies suggested that the smoking group, liver metastasis group, and brain metastasis group may have a potential OS benefit."

基金机构：　

基金资助正文：